医疗耗材行业周报：板块行情震荡，关注基本面改善的细分方向

Investment Rating - The industry rating for the medical consumables sector is "Overweight" [5][6][16] Core Insights - The medical consumables sector experienced a downward trend, with a decline of 4.73% last week [2][9] - The current PE ratio for the medical consumables sector is 33.97X, down 2.38 percentage points from the previous week, indicating that valuations are still at historical lows [3][12] - The performance of listed companies in the medical consumables sector showed a mixed trend, with 30 out of 45 companies reporting revenue growth year-on-year in the first three quarters of 2024 [4][13] Summary by Sections Industry Performance - The medical consumables sector reported a decline of 4.73%, with the index closing at 5346.8 points [2][9] - The sector's performance was influenced by broader market trends, with the medical and biological sector also declining by 2.9% [2][9] Valuation Metrics - The PE ratio for the medical consumables sector is currently 33.97X, with a historical maximum of 56.19X and a minimum of 22.71X over the past year [3][12] - The PB ratio stands at 2.4X, with historical values ranging from 1.42X to 2.92X [3][12] Company Performance - In the first three quarters of 2024, 30 out of 45 listed medical consumables companies reported revenue growth, with 13 companies achieving growth rates exceeding 20% [4][13] - The interventional consumables segment showed strong performance, with most companies maintaining high growth rates [4][13][16] Industry Dynamics - The fifth batch of national procurement for high-value medical consumables was officially launched on November 1, 2024, affecting products like cochlear implants and peripheral vascular stents [14][15] - The overall sentiment in the sector is influenced by emotional factors and market fluctuations, with significant volatility observed recently [15][16] Investment Recommendations - The report suggests focusing on high-quality stocks in the interventional and electrophysiological consumables sectors, which have shown robust performance [6][16] - Attention should also be given to companies that performed well in their recent quarterly reports [6][16]